Abstract
Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related mortality worldwide and its incidence continues to rise. While cirrhosis underlies most cases of HCC, many molecular pathways are implicated in HCC carcinogenesis, including the TERT promoter mutation, Wnt/β-catenin, P53, Akt/mTOR, vascular endothelial growth factor receptor (VEGFR), and endothelial growth factor receptor (EGFR)/RAS/MAPK pathways. While the most widely used staging and treatment algorithm for HCC—the Barcelona Clinic Liver Cancer (BCLC) system—does not recommend systemic molecular therapy for early HCC, a variety of treatment options are available depending upon the stage of HCC at diagnosis. Determining the best treatment options must take into account not only the burden and extent of HCC, but also the patient’s performance status, underlying liver function, extra-hepatic disease and co-morbidities. Radiofrequency or microwave ablation, liver resection, or liver transplantation, all potential curative therapies for HCC, should be the first-line treatments when possible. For patients who are not candidates of curative treatments, locoregional therapies such as transarterial chemoembolization (TACE), transarterial radioembolization (TARE), and stereotactic body radiation (SBRT) can improve survival and quality of life. Sorafenib, a multi-kinase VEGF inhibitor, is the most widely used systemic chemotherapy approved as a first-line agent for unresectable or advanced HCC. Clinical trials are underway directed towards molecular therapies that target different aspects of the hepatocellular carcinogenesis cascade. Ideally, the goal of future therapy should be to target multiple pathways in the HCC cascade with combination treatments to achieve personalized care aimed at improving overall survival.
Similar content being viewed by others
References
Grandhi MS, Kim AK, Ronnekleiv-Kelly SM, Kamel IR, Ghasebeh MA, Pawlik TM. Hepatocellular carcinoma: from diagnosis to treatment. Surg Oncol 2016;25(2):74–85
Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet 2012;379(9822):1245–1255
Zucman-Rossi J, Villanueva A, Nault JC, Llovet JM. Genetic landscape and biomarkers of hepatocellular carcinoma. Gastroenterology 2015;149(5):1226–1239
Calderaro J, et al. Histological subtypes of hepatocellular carcinoma are related to gene mutations and molecular tumour classification. J Hepatol 2017;67(4):727–738
Schulze K, et al. Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets. Nat Genet 2015;47(5):505–511
Ally A, et al. Comprehensive and integrative genomic characterization of hepatocellular carcinoma. Cell 2017;169(7):1327–1341
Villanueva A, Newell P, Chiang DY, Friedman SL, Llovet JM. Genomics and signaling pathways in hepatocellular carcinoma. Semin Liver Dis 2007;27(1):55–76
Schlachterman A, Craft WW, Hilgenfeldt E, Mitra A, Cabrera R. Current and future treatments for hepatocellular carcinoma. World J Gastroenterol 2015;21(28):8478–8491
Shin JW. Molecular targeted therapy for hepatocellular carcinoma: current and future. World J Gastroenterol 2013;19(37):6144
Ma L, Chua MS, Andrisani O, So S. Epigenetics in hepatocellular carcinoma: an update and future therapy perspectives. World J Gastroenterol 2014;20(2):333–345
Heimbach JK, et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology 2018;67(1):358–380
Omata M, et al. Asia–Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hepatol Int 2017;11(4):317–370
Silva MA, Hegab B, Hyde C, Guo B, Buckels JAC, Mirza DF. Needle track seeding following biopsy of liver lesions in the diagnosis of hepatocellular cancer: a systematic review and meta-analysis. Gut 2008;57(11):1592–1596
Guyatt GH, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. Chin J Evid Based Med 2009;9(1):8–11
Sullivan RCCCRFBDNWAGBZMPEGS. Imaging techniques for the diagnosis of hepatocellular carcinoma a systematic review and meta-analysis. Ann Intern Med 2015;162:697–711
Furlan A, et al. Hepatocellular carcinoma in cirrhotic patients at multidetector CT: hepatic venous phase versus delayed phase for the detection of tumour washout. Br J Radiol 2011;84(1001):403–412
Faria SC, Szklaruk J, Kaseb AO, Hassabo HM, Elsayes KM. TNM/Okuda/Barcelona/UNOS/CLIP international multidisciplinary classification of hepatocellular carcinoma: concepts, perspectives, and radiologic implications. Abdom Imaging 2014;39(5):1070–1087
Duseja A. Staging of hepatocellular carcinoma. J Clin Exp Hepatol 2014;4(August):S74–S79
Sun H, Song T. Hepatocellular carcinoma: advances in diagnostic imaging. Drug Discov Ther 2015;9(5):310–318
Maida M, Orlando E, Cammà C, Cabibbo G. Staging systems of hepatocellular carcinoma: a review of literature. World J Gastroenterol 2014;20(15):4141–4150
Saraswat VA, Pandey G, Shetty S. Treatment algorithms for managing hepatocellular carcinoma. J Clin Exp Hepatol 2014;4(August):S80–S89
Dufour JF, et al. Clinical practice guidelines EASL—EORTC clinical practice guidelines: management of hepatocellular carcinoma European Organisation for Research and Treatment of Cancer. J Hepatol 2012;56(4):908–943
Kim YS, Lim HK, Rhim H, Lee MW. Ablation of hepatocellular carcinoma. Best Pract Res Clin Gastroenterol 2014;28(5):897–908
Livraghi T. Radiofrequency ablation of hepatocellular carcinoma. Surg Oncol Clin N Am 2011;20(2):281–299
Kasugai H, Osaki Y, Oka H, Kudo M, Seki T. Severe complications of radiofrequency ablation therapy for hepatocellular carcinoma: an analysis of 3,891 ablations in 2,614 patients. Oncology 2007;72(SUPPL 1):72–75
Mulier S, et al. Complications of radiofrequency coagulation of liver tumours. Br J Surg 2002;89(10):1206–1222
Nishikawa H, Kimura T, Kita R, Osaki Y. Radiofrequency ablation for hepatocellular carcinoma. Int J Hyperth 2013;29(6):558–568
Shiina S, et al. Radiofrequency ablation for hepatocellular carcinoma: 10-year outcome and prognostic factors. Am J Gastroenterol 2012;107(4):569–577
Chen MS, et al. A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma. Ann Surg 2006;243(3):321–328
Feng K, et al. A randomized controlled trial of radiofrequency ablation and surgical resection in the treatment of small hepatocellular carcinoma. J Hepatol 2012;57(4):794–802
Huang J, et al. A randomized trial comparing radiofrequency ablation and surgical resection for HCC conforming to the Milan criteria. Ann Surg 2010;252(6):903–912
Zhou Y, et al. Meta-analysis of radiofrequency ablation versus hepatic resection for small hepatocellular carcinoma. BMC Gastroenterol 2010;10:1–7
Li L, Zhang J, Liu X, Li X, Jiao B, Kang T. Clinical outcomes of radiofrequency ablation and surgical resection for small hepatocellular carcinoma: a meta-analysis. J Gastroenterol Hepatol 2012;27(1):51–58
Earl TM, Chapman WC. Hepatocellular carcinoma: resection versus transplantation. Semin Liver Dis 2013;33(3):282–292
Fan ST. Hepatocellular carcinoma—resection or transplant? Nat Rev Gastroenterol Hepatol 2012;9(12):732–737
Fonseca AL, Cha CH. Hepatocellular carcinoma : a comprehensive overview of surgical therapy. J Surg Oncol 2014;110:712–719
Vitale A, et al. Personalized treatment of patients with very early hepatocellular carcinoma. J Hepatol 2017;66(2):412–423
Llovet JM, Fuster J, Bruix J. Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation. Hepatology 1999;30(6):1434–1440
Sapisochin G, et al. Single HCC in cirrhotic patients: liver resection or liver transplantation? Long-term outcome according to an intention-to-treat basis. Ann Surg Oncol 2013;20(4):1194–1202
Roayaie S. Resection of hepatocellular cancer ≤ 2 CM: results from two western centers. Hepatology 2013;57(4):1426–1435
Fahrner R. Liver transplantation for hepatocellular carcinoma—factors influencing outcome and disease-free survival. World J Gastroenterol 2015;21(42):12071
Mazzaferro V, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996;334(11):693–699
Yao FY, et al. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology 2001;33(6):1394–1403
Mazzaferro V, et al. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol 2009;10(1):35–43
Duffy JP, et al. Liver transplantation criteria for hepatocellular carcinoma should be expanded: a 22-year experience with 467 patients at UCLA. Ann Surg 2007;246(3):502–509
Livraghi T, Mäkisalo H, Line PD. Treatment options in hepatocellular carcinoma today. Scand J Surg 2011;100(1):22–29
Guy J, Kelley RK, Roberts J, Kerlan R, Yao F, Terrault N. Multidisciplinary management of hepatocellular carcinoma. Clin Gastroenterol Hepatol 2012;10(4):354–362
Facciuto ME, et al. Surgical dilemma: liver resection or liver transplantation for hepatocellular carcinoma and cirrhosis. Intention-to-treat analysis in patients within and outwith Milan criteria. Hpb 2009;11(5):398–404
Tsochatzis EA, Fatourou E, O’Beirne J, Meyer T, Burroughs AK. Transarterial chemoembolization and bland embolization for hepatocellular carcinoma. World J Gastroenterol 2014;20(12):3069–3077
Facciorusso A, Licinio R, Muscatiello N, Di Leo A, Barone M. Transarterial chemoembolization: evidences from the literature and applications in hepatocellular carcinoma patients. World J Hepatol 2015;7(16):2009–2019
Habib A, Desai K, Hickey R, Thornburg B, Lewandowski R, Salem R. Locoregional therapy of hepatocellular carcinoma. Clin Liver Dis 2015;19(2):401–420
Lencioni R. Chemoembolization for hepatocellular carcinoma. Semin Oncol 2012;39(4):503–509
Gao ZH, Bai DS, Jiang GQ, Jin SJ. Review of preoperative transarterial chemoembolization for resectable hepatocellular carcinoma. World J Hepatol 2015;7(1):40–43
Han K, Kim JH. Transarterial chemoembolization in hepatocellular carcinoma treatment: barcelona clinic liver cancer staging system. World J Gastroenterol 2015;21(36):10327–10335
Jazieh KA, Arabi M, Khankan AA. Transarterial therapy: an evolving treatment modality of hepatocellular carcinoma. Saudi J Gastroenterol 2014;20(6):333–341
Lencioni R, Crocetti L. Local-regional treatment of hepatocellular carcinoma. Radiology 2012;262(1):43–58
Lencioni R, Petruzzi P, Crocetti L. Chemoembolization of hepatocellular carcinoma. Semin Interv Radiol 2013;30(1):3–11
Willatt JM, Francis IR, Novelli PM, Vellody R, Pandya A, Krishnamurthy VN. Interventional therapies for hepatocellular carcinoma. Cancer Imaging 2012;12(1):79–88
Boyvat F. Interventional radiologic treatment of hepatocellular carcinoma. Exp Clin Transplant 2017;15:25–30
Sangro B, Iñarrairaegui M, Bilbao JI. Radioembolization for hepatocellular carcinoma. J Hepatol 2012;56(2):464–473
Sangro B, Salem R, Kennedy A, Coldwell D, Wasan H. Radioembolization for hepatocellular carcinoma: a review of the evidence and treatment recommendations. Am J Clin Oncol 2011;34(4):422–431
Sacco R, et al. Transarterial radioembolization for hepatocellular carcinoma: a review. J Hepatocell Carcinoma 2016;3:25–29
Golfieri R, Pettinato C, Cappelli A. Transarterial radioembolization using yttrium-90 microspheres in the treatment of hepatocellular carcinoma: a review on clinical utility and developments. J Hepatocell Carcinoma 2014;1:163–182
Salem R, Lewandowski RJ. Chemoembolization adn radioembolization for hepatocellular carcinoma. Clin Gastroenterol Hepatol 2013;11(6):1–16
Salem R, et al. Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma. Gastroenterology 2011;140(2):497–507
Bujold A, Dawson LA. Radiothérapie stéréotaxique et radiothérapie interne sélective du carcinome hépatocellulaire. Cancer Radiother 2011;15(1):54–63
Sangro B, et al. Radioembolization using 90Y-resin microspheres for patients with advanced hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 2006;66(3):792–800
Feng M, Ben-Josef E. Radiation therapy for hepatocellular carcinoma. Semin Radiat Oncol 2011;21(4):271–277
Meng M, et al. Stereotactic body radiation therapy: a novel treatment modality for inoperable hepatocellular carcinoma. Drug Discov Ther 2015;9(5):372–379
Kondo Y, Kimura O, Shimosegawa T. Radiation therapy has been shown to be adaptable for various stages of hepatocellular carcinoma. World J Gastroenterol 2015;21(1):94–101
Sanuki N, Takeda A, Kunieda E. Role of stereotactic body radiation therapy for hepatocellular carcinoma. World J Gastroenterol 2014;20(12):3100–3111
Yao FY, et al. Excellent outcome following down-staging of hepatocellular carcinoma prior to liver transplantation: an intention-to-treat analysis. Hepatology 2008;48(3):819–827
Toso C, Mentha G, Kneteman NM, Majno P. The place of downstaging for hepatocellular carcinoma. J Hepatol 2010;52(6):930–936
Majno PE, et al. Influence of preoperative transarterial lipiodol chemoembolization on resection and transplantation for hepatocellular carcinoma in patients with cirrhosis. Ann Surg 1997;226(6):688–703
Lewandowski RJ, et al. A comparative analysis of transarterial downstaging for hepatocellular carcinoma: chemoembolization versus radioembolization. Am J Transplant 2009;9(8):1920–1928
Pompili M, Francica G, Ponziani FR, Iezzi R, Avolio AW. Bridging and downstaging treatments for hepatocellular carcinoma in patients on the waiting list for liver transplantation. World J Gastroenterol 2013;19(43):7515–7530
Parikh N, Waljee A, Singal A. Downstaging hepatocellular carcinoma: a systematic review and pooled analysis Neehar. Liver Transplant 2007;21:1142–1152
Belghiti J, et al. Resection prior to liver transplantation for hepatocellular carcinoma. Ann Surg 2003;238(6):885–893
Cheng A-L, et al. Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase III trial. J Clin Oncol 2013;31(32):4067–4075
Ge S, Huang D. Systemic therapies for hepatocellular carcinoma. Drug Discov Ther 2015;9(5):352–362
Llovet JM, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359(4):378–390
Cheng AL, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009;10(1):25–34
Johnson PJ, et al. Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study. J Clin Oncol 2013;31(28):3517–3524
Llovet JM, et al. Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study. J Clin Oncol 2013;31(28):3509–3516
Cainap C, et al. Linifanib versus sorafenib in patients with advanced hepatocellular carcinoma: results of a randomized phase III trial. J Clin Oncol 2015;33(2):172–179
Zhu AX, et al. SEARCH: a phase III, randomized, double-blind, placebo-controlled trial of sorafenib plus erlotinib in patients with advanced hepatocellular carcinoma. J Clin Oncol 2015;33(6):559–566
Abou-Alfa GK, et al. A phase II study of cixutumumab (IMC-A12, NSC742460) in advanced hepatocellular carcinoma. J Hepatol 2014;60(2):319–324
US Food and Drug Administration. FDA approves lenvatinib for unresectable hepatocellular carcinoma. Silver Spring: US Department of Health and Human Services; 2018
Kudo M, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet 2018;391(10126):1163–1173
Approved drugs - FDA grants accelerated approval to nivolumab for HCC previously treated with sorafenib. Edited by Center for Drug Evaluation and Research, US Food and Drug Administration Home Page, Center for Drug Evaluation and Research. 2017. https://www.fda.gov/drugs/informationondrugs/approveddrugs/ucm577166.htm
Approved Drugs - Regorafenib. Edited by Center for Drug Evaluation and Research, US Food and Drug Administration Home Page, Center for Drug Evaluation and Research. 2017. https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm555548.htm
Bruix J, et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2017;389(10064):56–66
El-Khoueiry AB, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet 2017;389(10088):2492–2502
Abou-Alfa GK, et al. Cabozantinib in patients with advanced and progressing hepatocellular carcinoma. N Engl J Med 2018;379(1):54–63
Zhu AX, et al. Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol 2015;16(7):859–870
Patt YZ, et al. Oral capecitabine for the treatment of hepatocellular carcinoma, cholangiocarcinoma, and gallbladder carcinoma. Cancer 2004;101(3):578–586
Zaanan A, et al. Gemcitabine plus oxaliplatin in advanced hepatocellular carcinoma: a large multicenter AGEO study. J Hepatol 2013;58(1):81–88
Qin S, et al. Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia. J Clin Oncol 2013;31(28):3501–3508
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
TC has no conflicts of interest to report. AP is on the speaker’s bureau for Eisai and BTG and serves on advisory board for Wako Diagnostics..
Ethical approval
Not applicable.
Informed consent
Not applicable as this is a review article.
Rights and permissions
About this article
Cite this article
Couri, T., Pillai, A. Goals and targets for personalized therapy for HCC. Hepatol Int 13, 125–137 (2019). https://doi.org/10.1007/s12072-018-9919-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12072-018-9919-1